LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology firm growing therapies for sufferers with kidney illness (the “Firm” or “Unicycive”), immediately introduced that Shalabh Gupta, M.D., Chief Government Officer, will take part in a fireplace chat on the Guggenheim Rising Outlook: Biotech Summit on Wednesday, February 11, 2026, at 1:30 p.m. ET.
A hyperlink to the stay and archived webcast could also be accessed on the Unicycive web site beneath the Traders part: Occasions and Displays. To schedule a 1×1 assembly with administration, please contact your Guggenheim convention consultant.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology firm growing novel remedies for kidney illnesses. Unicycive’s lead investigational remedy is oxylanthanum carbonate, a novel phosphate binding agent at the moment beneath assessment by the U.S. Meals and Drug Administration (FDA) for the remedy of hyperphosphatemia in sufferers with continual kidney illness who’re on dialysis. Unicycive’s second investigational remedy UNI-494 is meant for the remedy of circumstances associated to acute kidney damage. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Perform (DGF) in kidney transplant sufferers and has accomplished a Section 1 dose-ranging security examine in wholesome volunteers. For extra data, please go to Unicycive.com and observe us on LinkedIn and X.
Investor Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Layne Litsinger
Actual Chemistry
llitsinger@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
Source link
#Unicycive #Therapeutics #Take part #Hearth #Chat #Guggenheims #Rising #Outlook #Biotech #Summit
